RxNews Recap for Monday 12-28-09 Print E-mail
By Mary Davila   
Monday, 28 December 2009 20:44
Below is a list of the companies that made news in the healthcare sector on Monday, December 28, 2009.


Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced today financial results for the three months and twelve months ended September 30, 2009.

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced it is instituting several actions to become a fully reporting organization, improve transparency to investors and migrate the trading of its common shares to the over-the-counter market.

BioTech Medics, Inc. (PINKSHEETS: BMCS) CEO Keith Houser has sent a letter to Texas Attorney General Greg Abbott encouraging him to fight the "outrageous" Obamacare plan and the Senate's decision to give Nebraska and other states multimillion-dollar tax breaks as part of a deal to get votes for the health care plan.

Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors. CGEN-671 in a membrane splice variant of CD55, a known drug target for gastric cancer for which monoclonal antibody (mAb) therapeutics are in clinical development by others.

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that on December 24, 2009, CTI's Board of Directors (the "Board of Directors") approved and adopted a Shareholder Rights Plan (the "Rights Plan") in which one preferred stock purchase right will be distributed for each common share held as of the close of business on January 7, 2010.

Cambridge Heart, Inc. (OTCBB: CAMH), today announced that it has completed a private placement of Series D convertible preferred stock, raising proceeds of approximately $1.8 million.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that its partnership with the New England Patriots Radio Network, WBZ FM 98.5 The Sports Hub, to recognize innovative science teachers in middle schools and high schools throughout New England selected 11 science “Teachers of the Week” during the course of the football season.

GeneLink BioSciences, Inc., (OTC Bulletin Board: GNLK) a leading consumer genomics and biotechnology company (www.genelinkbio.com), is pleased to announce the appointment of David L. Macdonald as its interim Chief Executive Officer, effective December 28, 2009.

Inhibitex, Inc. (Nasdaq: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("NASDAQ") stating that for 30 consecutive business days the bid price for the Company's common stock has closed below the minimum $1.00 per share as required by Marketplace Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement.

Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today the publication of an article in the January 2010 edition of Infection and Immunity, detailing the characteristics of several immunodominant regions of ricin A chain, the antigenic component of RiVax((TM)).



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter